Verification and Unmasking of Widely Used Human Esophageal Adenocarcinoma Cell Lines

Jurjen J. Boonstra(National Cancer Institute), Ronald van Marion(Johns Hopkins Medicine), David G. Beer(Memorial Sloan Kettering Cancer Center), Lin Lin(Erasmus MC), Paula Chaves(Memorial Sloan Kettering Cancer Center), Catarina Ribeiro(University of Toyama), António Dias Pereira(University of Michigan), Lúcia Roque(Johns Hopkins Medicine), S. Jane Darnton(National Cancer Institute), Nasser K. Altorki(Johns Hopkins Medicine), David S. Schrump(Johns Hopkins Medicine), David S. Klimstra(Center for Cancer Research), Laura H. Tang(Memorial Sloan Kettering Cancer Center), James R. Eshleman(Memorial Sloan Kettering Cancer Center), Héctor M. Álvarez(Johns Hopkins University), Yutaka Shimada(Johns Hopkins Medicine), Herman van Dekken(Johns Hopkins Medicine), Hugo W. Tilanus(Johns Hopkins University), Winand N.M. Dinjens(Johns Hopkins Medicine)
JNCI Journal of the National Cancer Institute
January 15, 2010
Cited by 128Open Access
Full Text

Abstract

For decades, hundreds of different human tumor type-specific cell lines have been used in experimental cancer research as models for their respective tumors. The veracity of experimental results for a specific tumor type relies on the correct derivation of the cell line. In a worldwide effort, we verified the authenticity of all available esophageal adenocarcinoma (EAC) cell lines. We proved that the frequently used cell lines SEG-1 and BIC-1 and the SK-GT-5 cell line are in fact cell lines from other tumor types. Experimental results based on these contaminated cell lines have led to ongoing clinical trials recruiting EAC patients, to more than 100 scientific publications, and to at least three National Institutes of Health cancer research grants and 11 US patents, which emphasizes the importance of our findings. Widespread use of contaminated cell lines threatens the development of treatment strategies for EAC.


Related Papers

No related papers found

Powered by citation graph analysis